Neuronal pentraxins (NPTX) and their corresponding receptors (NPTXR) have been studied as synapse-associated proteins in the nervous system, but their role in cancer is largely unknown.
The genetic nature of this disease has made it difficult to develop targeted therapies: only a few genes have been found mutated, and the occurrence of the corresponding genetic lesions is less than 10%, usually in the 1-3% range (2) . Other potential targets have been identified by analysis of copy number variation and epigenetic modifications. However, most of these targets [MYCN, AURKA (3), CHD5 (4), ATRX (5), ARID1A/B (6), ODC (7)] are cytoplasmic or nuclear, making them challenging to target therapeutically. The transmembrane proteins ALK (8) and TrkB (9) are mutated or overexpressed in a substantial number of high-risk NB patients, representing potentially interesting targets. CD19 and GD 2 membrane antigens (10) are being pursued for targeted radiation therapy and nanoparticle-driven drug delivery (11) as well as for antibodymediated immunotherapy (12) , with some success in the treatment and prevention of NB.
While genetic and genomic analyses are powerful approaches for identifying potential therapeutic targets, they do not necessarily reflect the actual amounts, localization, and reciprocal interactions of the gene-encoded proteins. In addition, they provide data only on the tumor cells, without taking into account their microenvironment and tumor/normal tissue interactions, which play critical roles in tumorigenesis (13) . Therefore, we have recently developed a multidisciplinary approach to investigate high-risk NB in the context of its native protein architecture, and characterized a set of specific peptide ligand motifs for NB-targeted drug delivery in vivo (14) .
In the present work, we identify neuronal pentraxin-2 (NPTX2) and its receptor (NPTXR)
as a functional ligand/receptor system in NB. Neuronal pentraxins were originally described in the brain as synapse-associated proteins (15), although they are expressed also in few other tissues. The analysis was performed on the SEQC (SEquencing Quality Control) neuroblastoma project dataset, and the significance was evaluated by Chi-square test.
Research. 
Results and Discussion
We have recently isolated a peptide motif as specific ligand for mouse models of human NB (14) . To identify corresponding native ligands, we performed a BLAST analysis against the human and mouse proteomes. Four transmembrane or secreted proteins were retrieved with high homology scores. Of these, ephrin-A1 and α 11 integrin were not further studied because their expression was barely detectable in NB tissues, as evaluated by IF staining followed by confocal microscopy and quantification (Fig. S1 , fluorescent pixels × 10 (Fig. 1B) and, in association with a detailed morphological analysis by IHC, revealed that, while NPTX2 expression is confined to blood vessel-forming and/or surrounding cells (Fig.   1C, black arrows) , NPTXR is present in high amounts also in neuroblastic cells (Fig. 1C, red arrows). These data are consistent with the in vitro expression levels of NPTX2 (low) and NPTXR (medium) in these same NB cell lines, as evaluated by flow cytometry (Fig. S2C) and confirmed by immunoblot (Fig. S2D) . Non-tumor tissues (kidney, adrenal gland, liver) from control animals were largely negative for NPTX2 and NPTXR expression (Fig. S3) . These findings suggest that the onset and/or progression of NB induce the expression of both ligand and receptor in normal 
this hypothesis, we first used two mouse models obtained by orthotopic implantation of GI-LI-N and IMR-32 cells into the adrenal glands. We injected cells alone or in the presence of either control (CTRL) or NB-targeting (TARG) peptide, or in the presence of either anti-NPTX2 or anti-NPTXR antibody. After 30 days, mice were killed and organs recovered for tumor burden analysis. We observed a reduction in tumor volume in mice receiving NB cells in the presence of the targeting peptide, as well as of the specific antibodies, compared to cells alone (not shown) or cells plus control peptide (Fig. 1D) . This reduction was significant for all the experimental points in the GI-LI-N model, and for the anti-NPTXR experimental point in the IMR-32 model. A higher affinity/blocking efficiency of the anti-NPTXR monoclonal antibody in comparison to both the peptide and the polyclonal anti-NPTX2 antibody, coupled with slightly different expression levels of the targets, might account for the different significance observed. After treatments, the overall amounts and distribution of both proteins, as well as the vascular architecture, were maintained (Fig. 1E) , suggesting that interference with NPTX2 and NPTXR possibly affects early steps of tumor/normal tissue reciprocal recognition, rather than influencing successive tissue organization during tumor progression. (Fig. 2A) . We investigated whether this effect was related to NPTX2/NPTXR- (Fig.   2B ). All these microenvironment cells express both NPTX2 and NPTXR; however, NPTXR levels are markedly higher in pericytes (Fig. S2D-E) , possibly accounting for the weaker inhibition observed. We also evaluated whether NPTX2 and/or NPTXR had a role in NB cell migration towards normal microenvironment cells. For these assays, we chose the SH-SY5Y cell line after extensive characterization of the migratory properties in all NB cell lines (Fig. S4) . Interestingly, attraction of SH-SY5Y was increased by treatment with either targeting peptide or anti-NPTXR antibody, while interfering with NPTX2 was ineffective (Fig. 2C) . Together, these data show that NPTX2 and NPTXR affect the spatial organization and reciprocal recognition of neuroblasts and normal cells. They demonstrate that, in this setting, (i) the NPTX2/NPTXR pathway has a proadhesive effect, (ii) NPTXR, possibly activated by an alternative ligand such as NPTX1 (18) , has an anti-migratory effect, and (iii) both functions are reverted by a specific targeting of NPTX2 and/or NPTXR.
Having shown that NPTX2 and NPTXR are potential targets in NB in vivo and in vitro, we evaluated their expression in human NB samples. The overall tissue distribution of both proteins was similar to that seen in the mouse models, although more background was visible in the staining for NPTX2, due to technical issues (FFPE mouse samples versus snap-frozen human specimens) (Fig. 3A) . Notably, in contrast to the high amounts of both NPTX2 and NPTXR detected in NB, undetectable to low expression of these proteins is reported by the Human Protein Atlas (19) for the same normal tissues that we evaluated in mice (Fig. S5 ). These data demonstrate that both proteins are overexpressed in NB in clinical settings. 
This finding led us to investigate a possible involvement for either protein during the progression of human NB. For this purpose, we exploited public microarray expression data that we evaluated through the "R2 microarray analysis and visualization platform". Analysis of a large patient dataset (SEQC, n=498) revealed that high levels of NPTX2 strongly correlated with poor overall survival (P = 3.2e-06). Unexpectedly, NPTXR had a different trend, although with lower significance (P = 0.019) (Fig. 3B) . One might speculate a possible explanation for this paradoxical result is that, while NPTX2 localizes prevalently to vascular compartments, NPTXR is expressed also by tumor cells distant from the blood vessels ( Fig. 1C and E) . It is therefore conceivable that a substantial amount of the receptor binds to an alternative pentraxin ligand (18, 20) , with a different biological outcome. Unfortunately, the SEQC dataset reports only a whole-tissue mRNA expression analysis, from which it is impossible to distinguish among the different species of NPTXR. The poor prognostic value of NPTX2 was not a surrogate for endothelial cell content:
another endothelial expressed gene, VE-cadherin followed an opposite trend and correlated with good overall survival (P = 6.1e-05) (Fig. 3B) .
In conclusion, we show that NPTX2 and NPTXR mediate tumor/normal cell recognition in NB and that interfering with this ligand/receptor system is a potential approach towards the development of an innovative targeted therapy. We summarize the proposed mechanism in Fig.   4 . Finally, we show that NPTX2 is a novel poor prognosis tumor marker for NB patients. 
